A citation-based method for searching scientific literature

Anne L Peters, Robert R Henry, Payal Thakkar, Cindy Tong, Maria Alba. Diabetes Care 2016
Times Cited: 57



Julio Rosenstock, Jan Marquard, Lori M Laffel, Dietmar Neubacher, Stefan Kaspers, David Z Cherney, Bernard Zinman, Jay S Skyler, Jyothis George, Nima Soleymanlou, Bruce A Perkins. Diabetes Care 2018
Times Cited: 116




List of shared articles



Times cited

Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy.
Biff F Palmer, Deborah J Clegg. Clin J Am Soc Nephrol 2021
1



Empagliflozin in type 1 diabetes.
Chantal Mathieu, Laura Van Den Mooter, Bert Eeckhout. Diabetes Metab Syndr Obes 2019
3


SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects.
Birgit Janssens, Simon Caerels, Chantal Mathieu. Ther Adv Endocrinol Metab 2020
4

SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes.
Huan Chen, Yochai Birnbaum, Regina Ye, Hsiu-Chiung Yang, Mandeep Bajaj, Yumei Ye. Cardiovasc Drugs Ther 2021
0

Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes.
Roselle A Herring, Fariba Shojaee-Moradie, Robert Garesse, Mary Stevenage, Nicola Jackson, Barbara A Fielding, Agampodi Mendis, Sigurd Johnsen, A Margot Umpleby, Melanie Davies,[...]. Diabetes Care 2020
5


Strategically Playing with Fire: SGLT Inhibitors as Possible Adjunct to Closed-Loop Insulin Therapy.
Melissa-Rosina Pasqua, Michael A Tsoukas, Ahmad Haidar. J Diabetes Sci Technol 2021
0